Hrt Financial LP Alaunos Therapeutics, Inc. Transaction History

Hrt Financial LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$0.5 - $261.0 $9,128 - $4.76 Million	18,256 New	18,256 $11,000
Q1 2022 May 16, 2022	SELL	$0.62 - $1.17 $29,799 - $56,233	-48,063 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$1.09 - $1.89 $644,346 - $1.12 Million	-591,144 Reduced 92.48%	48,063 $52,000
Q3 2021 Nov 15, 2021	BUY	$1.44 - $2.73 $572,090 - $1.08 Million	397,285 Added 164.22%	639,207 $1.16 Million
Q2 2021 Aug 16, 2021	BUY	$2.63 - $3.67 $636,254 - $887,853	241,922 New	241,922 $638,000
Q4 2019 Feb 14, 2020	SELL	$3.95 - $5.35 $146,074 - $197,848	-36,981 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$4.13 - $6.94 $152,731 - $256,648	36,981 New	36,981 $158,000

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $443M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.